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ABSTRACT
Objective: To report the case of a patient
treated with leflunomide that presented with
chronic diarrhea associated with high
teriflunomide blood concentration.
Case Summary: An 84-year-old woman taking
leflunomide 20 mg once daily for the past 2 years
to treat rheumatoid arthritis (RA) was
investigated for severe chronic diarrhea that had
been worsening for the past 5 months. The
patient’s general condition progressively
deteriorated and included electrolyte imbalances
and a transient loss of consciousness. Therefore,
hospitalization was required. Teriflunomide
blood concentration was 156 mg/L. After
11 days of cholestyramine washout therapy,
teriflunomide blood concentration was reduced
to 6 mg/L. As the teriflunomide levels decreased,
diarrhea improved. All other possible causes of
diarrhea were ruled out. The patient’s diarrhea
finally resolved 26 days after treatment with
cholestyramine.
Discussion: Diarrhea is a known adverse effect
of leflunomide. In this report, the severe
diarrhea was associated with high blood
teriflunomide concentrations. Available data
suggests an association between teriflunomide
concentrations greater than 50 mg/L and lower
disease activity, but toxic teriflunomide levels
still have to be clarified.
Conclusion: Further studies are needed to
establish the optimal therapeutic levels of
teriflunomide. However, therapeutic drug
monitoring of teriflunomide blood
concentrations may be helpful to improve
effectiveness and to prevent toxicity in patients
taking leflunomide for RA, particularly in those
with suboptimal therapeutic response to
leflunomide or in patients with toxicity
suspected to be induced by leflunomide.
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INTRODUCTION
Leflunomide is a disease-modifying
antirheumatic drug (DMARD) approved since
1998 for the treatment of rheumatoid arthritis
(RA). Teriflunomide, the active metabolite of
leflunomide, inhibits dihydroorotate
dehydrogenase, an essential enzyme for de
novo synthesis of pyrimidines. As a
consequence, the division of activated
T lymphocytes, which plays an important role
in RA pathology, is inhibited [1]. Leflunomide is
generally considered when other DMARDs are
not effective or not tolerated [2]. It may also be
used as an adjunct therapy to methotrexate [3].
One advantage of leflunomide over biological
agents is its low cost.
Leflunomide is well absorbed orally, with an
estimated bioavailability around 80%.
Leflunomide is a prodrug that is almost
completely metabolized in the gut into the
active metabolite teriflunomide (also known as
A77-1726). This biotransformation occurs by a
non-enzymatic reaction in the submucosal wall
of the intestinal tract [4]. More than 99% of
teriflunomide is bound to proteins and its
half-life is approximately 15 days in RA
patients (14–18 days) [4, 5]. Teriflunomide is
excreted both in urine and in the feces. Its long
half-life is thought to be the result of a low
hepatic clearance and of an enterohepatic
recirculation (Fig. 1). Metabolism pathways of
leflunomide and teriflunomide are not yet
completely elucidated. Major metabolites
found in the urine included
4-(trifluoromethyl)aniline oxanilate,
methylhydroxyteriflunomide, and leflunomide
glucuronide. At the usual 20-mg daily dosage of
leflunomide, the expected teriflunomide plasma
concentration is around 35 mg/L [4]. No
clinically significant pharmacokinetic drug
interaction other than with cholestyramine
and activated charcoal was reported with
leflunomide or its metabolite [4–6]. These
agents are known to bind with teriflunomide
excreted in the bile, thus interrupting
enterohepatic recirculation and then
decreasing teriflunomide’s half-life to 24 h
[4–7]. Since leflunomide is almost completely
metabolized, it cannot be detected in the blood.
However, therapeutic drug monitoring is
available for teriflunomide.
Washout therapy with oral activated
charcoal 50 g four times daily or
cholestyramine 8 g orally three times daily for
11 days is recommended for patients who need
a rapid discontinuation of leflunomide. This
strategy is recommended in patients presenting
with an important side effect or in women
planning a pregnancy [8]. Otherwise,
teriflunomide may be detected in plasma for
2 years after the last dose [6]. Clinical success
with cholestyramine decontamination strategy
is also reported in patients featuring
leflunomide-induced pneumonitis, hepatitis,
or vasculitis [7, 9–11]. However, literature
describing the usefulness of teriflunomide
blood concentration monitoring is limited.
We describe the case of an 84-year-old
woman presenting with severe chronic
diarrhea associated with high teriflunomide
blood concentration.
CASE PRESENTATION
The patient was an 84-year-old woman who was
referred to the internal medicine service of a
university teaching hospital for severe chronic
diarrhea accompanied with electrolyte
imbalance and weight loss. She had been
suffering from severe diarrhea (2–5 profuse
liquid stools per day) for the past 5 months
and her condition progressively deteriorated.
Diarrhea was accompanied by neither
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abdominal pain nor nausea, but induced a
20-kg weight loss. Two weeks before referral,
the patient had presented to another hospital
with bloody stool. The computed tomography
(CT) scan was normal. The colonoscopy was
macroscopically normal with a normal colonic
mucosa aspect but the biopsy showed
nonspecific mild acute and subacute colitis
with no evidence of microscopic colitis.
The patient had the following comorbidities:
RA, diabetes, hypothyroidism, glaucoma,
dyslipidemia, hypertension, and hysterectomy.
Her usual medication is listed in Table 1. The
patient had no known allergy. She had previous
history of smoking (50 pack-years), but stopped
17 years earlier and she did not use any drugs or
alcohol. She had not received any antibiotics in
the previous 3 months and had no history of
irritable bowel syndrome. The patient did not
eat or drink sorbitol or other sugar
substitute-containing products and she had no
greasy stools. The patient had been taking
leflunomide for 2 years, because of a previous
unspecified gastrointestinal intolerance to
methotrexate.
For the first 12 days, she was investigated as
an outpatient. Initial blood tests revealed
hypokalemia (2.3 mmol/L), hypomagnesemia
(0.36 mmol/L), hypophosphatemia (0.75
mmol/L), and an acute kidney injury
(creatinine 157 lmol/L). Treatment included
rehydration and electrolyte supplements. Liver
function tests, lipase and blood counts (white
blood cells and platelets) including eosinophils
remained within the normal range with the
exception of a slight anemia (hemoglobin
119 g/L). All other laboratory results and vital
signs were within the normal range. Kidney
function improved overtime (creatinine
98 lmol/L). A gastroscopy was performed to
rule out malignancy. The exam only revealed a
small hiatal hernia. Anti-transglutaminase
antibody screening was negative. She had not
recently travelled and a stool parasite testing
was negative. Given the absence of any other
cause for diarrhea, metformin was stopped, a
teriflunomide dosage was performed, and
leflunomide was halved to 10 mg daily. A
follow-up appointment was scheduled a week
later (day 16).
On day 13, the patient was brought to the
emergency and was admitted to the internal
medicine ward because of a fall followed by a
transient loss of consciousness without any
traumatic injury. Blood work showed
persistent hypomagnesemia (0.42 mmol/L),
which was supplemented. Other electrolytes
were within the normal range and creatinine
was back to normal (72 lmol/L). ECG and
cerebral scan were unremarkable. Leflunomide
was discontinued along with solifenacin and










Fig. 1 Leﬂunomide metabolism pathway. LEF leﬂunomide, TERI teriﬂunomide, NER non-enzymatic reaction, TERI
metabolites 4-(triﬂuoromethyl)aniline oxanilate and methylhydroxyteriﬂunomide
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suspected. Further exams revealed no
orthostatic hypotension, normal
thyroid-stimulating hormone (TSH) (0.79 mIU/
L), and no relevant cardiac issues. The fall was
attributed to dehydration and electrolyte
imbalances from the diarrhea and furosemide
was then stopped. On day 15 a
Clostridium difficile screening assay was
performed and was negative. The patient was
still having about 4–5 liquid stools per day
without any abdominal pain or nausea.
On day 17, the serum teriflunomide dosage
previously drawn on day 6 came back to 156 mg/
L. Leflunomide overdosage was suspected as a
cause for diarrhea and oral cholestyramine 8 g
three times daily was started. Two days later,
cholestyramine was lowered to 8 g two times a
day, as per the patient’s desire. No improvement
in diarrhea symptoms was observed. On day 21,
cholestyramine was increased to three times a
day, to ensure optimal washout of teriflunomide.
An enteroscan was performed which revealed
normal images.
Loperamide 4 mg was started on day 23 to
alleviate the patient’s diarrhea at night.
Eleven days after initiation of cholestyramine,
another teriflunomide dosage was drawn and
the result, available on day 36, was 6 mg/L.
Cholestyramine was stopped after 14 days of
therapy (days 17–30) following an
improvement in the patient’s diarrhea
frequency and severity (2–3 liquid stools per
day). Vasoactive intestinal peptide screening
was also negative.
Although diarrhea slowly improved during
hospitalization, it was not completely resolved.
The patient was discharged on day 41 with
loperamide and oral magnesium oxide.
Diarrhea resolved around day 56, 26 days after
completion of the cholestyramine washout
therapy. Loperamide was then stopped. At that
time, electrolytes were all normal except for the
persistence of hypomagnesemia (0.52 mmol/L),
which was attributed to the long-term use of a
proton pump inhibitor [12]. Five months later,
the patient had recurrence of RA symptoms and
oral methotrexate was reintroduced with a
7.5-mg weekly dosage, which was well
tolerated and optimized to a 10-mg weekly
dosage.
Compliance with Ethics Guidelines
Informed consent was obtained from the
patient’s family for including the patient in
the case study.
DISCUSSION
One of the most common adverse effects of
leflunomide therapy for RA is diarrhea. It is
often mild, it usually improves after 6 months,
and it is rarely a reason for treatment
discontinuation [13, 14].
There are multiple medical causes for
chronic diarrhea and leflunomide toxicity
Table 1 Patient’s usual medication
Prednisone 5 mg daily
Leﬂunomide 20 mg daily
Diltiazem 120 mg at bedtime
Furosemide 20 mg daily
Atorvastatin 20 mg at bedtime
Metformin 500 mg three times daily
Esomeprazole 40 mg daily
Calcium carbonate 500 mg ? vitamin D 400IU two
times daily
Risedronate 35 mg once weekly
Solifenacin 10 mg daily
Multivitamin 1 tablet daily
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remains an exclusion diagnosis. In this patient
all other major causes of diarrhea were ruled
out. Therefore, suspicion for
leflunomide-induced diarrhea is high and
corroborated by high teriflunomide blood
concentration and nonspecific mild colitis.
Chronic diarrhea and weight loss have been
reported in patients taking leflunomide for long
periods of time. Two patients taking leflunomide
for more than 12 months and presenting chronic
diarrhea were reported [13]. Both patients had
endoscopy-visible positive colitis induced by
leflunomide; one had ulcerative colitis and the
other microscopic colitis, which our patient did
not have. Blood teriflunomide concentrations
were not monitored in these patients [13]. In this
case, the colon biopsy showed nonspecific mild
acute and subacute colitis. A high teriflunomide
blood level (156 mg/L) may have induced colitis,
which manifested as a chronic severe diarrhea.
However, whether diarrhea is the etiology or the
manifestation of the nonspecific mild colitis is
not known. Drug-induced colitis does exist, with
mofetil mycophenolate for example [13]. In this
case, the resolution of diarrhea after a successful
cholestyramine washout associated with a
decrease of the teriflunomide blood level
(6 mg/L) is also suggestive of a
leflunomide-induced toxicity. Application of
the Naranjo adverse drug reaction probability
scale indicates a probable relationship (score of
8).
There are two known possible washout
therapies for leflunomide-induced toxicity:
either 8 g of oral cholestyramine three times
daily for 11 days or 50 g of activated charcoal
four times daily for 11 days [6]. For both these
therapies, duration should be modulated
according to clinical and laboratory variables
[6]. In our case, cholestyramine should have
been continued when the second teriflunomide
dosage came back to 6 mg/L, as the
post-washout targeted dose is less than
0.02 mg/L [8, 15]. Given the patient’s
improvement, her intolerance to
cholestyramine taste and the important
decrease in teriflunomide levels,
cholestyramine was discontinued after 14 days
of washout therapy. The post-washout target of
teriflunomide less than 0.02 mg/L was not
reached. Thus, the remaining 6 mg/L of
teriflunomide might have contributed to the
remnant diarrhea. In most of the reported cases
of cholestyramine washout therapies were used
for 11 days, but teriflunomide levels are not
reported or were not determined [7, 9–11]. One
published report showed decreases in levels
consistent with ours (100 to 0.057 mg/L after
11 days of cholestyramine washout) [16].
There is limited data available on the target
of teriflunomide blood concentrations for
patients with RA. At the usual 20-mg daily
dosage of leflunomide, the expected
teriflunomide plasma concentration is around
35 mg/L [4]. Blood concentrations of
teriflunomide below 16 mg/L are associated
with poorer clinical response in RA [17]. A
correlation between teriflunomide
concentration above 50 mg/L and lower RA
disease activity is also mentioned [18]. Cutoff
concentrations at which toxicity should be
expected is unknown. However, a retrospective
review performed in liver and kidney transplant
recipients receiving leflunomide has shown that
a targeted leflunomide blood level above
100 mg/L was associated with dose-limiting
adverse effects in 25–35% of the patients [19].
In contrast, the case of an RA patient who
mistakenly took 120 mg of leflunomide daily
for a month did not report any adverse events
despite a teriflunomide dose of 100 mg/L [16].
Although the patient remained asymptomatic,
her blood levels were successfully reduced to
0.057 mg/L with 11 days of cholestyramine [16].
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Although no specific ranges have been
established for teriflunomide, blood
concentration monitoring may be helpful to
detect accumulation and toxicity [19]. Blood
concentration monitoring could also be useful
in RA patients who do not achieve adequate
response with standard leflunomide dose.
Our patient had a 156 mg/L teriflunomide
blood dose associated with severe chronic
diarrhea and nonspecific mild colitis. As
mentioned before, teriflunomide is excreted
both in urine and in the feces. In our case the
patient had moderately impaired renal function
(about 50 mL/min creatinine clearance). As the
patient had severe diarrhea, lower teriflunomide
concentration could have been expected. Severe
diarrhea may decrease the enterohepatic
circulation of teriflunomide excreted in the bile,
therefore increasing the excretion in the feces. A
pharmacogenetics study suggests that poor or
intermediate CYP2C19 metabolizers have more
side effects and are more likely to stop leflunomide
compared to extensive or ultra-rapid CYP2C19
metabolizers [20]. However, adverse events are not
always predicted by teriflunomide blood
concentrations and could possibility be the
result of accumulation of other metabolites.
Whether our patient’s presentation is the result
of genetic polymorphism is unknown because her
CYP2C19 phenotype and genotype were not
assessed. Genetic polymorphism remains a
plausible hypothesis.
CONCLUSION
We report the case of a patient who presented
with severe diarrhea that was attributed to
leflunomide toxicity featuring high
teriflunomide blood concentration.
Cholestyramine washout therapy successfully
decreased teriflunomide blood concentration
from 156 to 6 mg/L, led to clinical
improvement, and ultimately led to the
resolution of diarrhea. Further studies are
needed to establish the optimal therapeutic
levels of teriflunomide in RA. However,
therapeutic drug monitoring of teriflunomide
blood concentrations may be helpful to improve
effectiveness and to prevent toxicity in patients
taking leflunomide for RA, particularly in those
with suboptimal therapeutic response to
leflunomide or in patients with toxicity
suspected to be induced by leflunomide.
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